Nucleascope is a European portal dedicated to nuclear medicine physicians, radiopharmacists, technologists and medical physicists. Showcase your tracers, clinical trials and theranostics solutions to a specialised, independent audience across 9 European countries.
✉ Contact us for a tailored offerEach format is designed to showcase your innovation while respecting the site's editorial independence and the community's scientific expectations.
Associate your brand with a monthly scientific dossier written by our team and read across the community.
Dedicated banner on PET tracer and radioligand therapy (RLT) pages, close to prescribing physicians.
Promote your trials open for recruitment directly to centres relevant to your indication.
Independent, compliant with European regulatory requirements, and exclusively dedicated to professionals in the speciality.
Site designed for nuclear medicine physicians, radiopharmacists, technologists and medical physicists. Technical content with specialised terminology.
Sponsored content is clearly labelled, scientific editorial line preserved.
Distribution can be targeted by country, region or facility type (university hospital, private, public).
Adapted to regulatory constraints on pharmaceutical communication in Europe.
Simultaneous distribution in French, English, Dutch, German, Spanish and Italian.
Each partnership is defined according to your objectives: awareness, trial recruitment, product launch.
Nucleascope is consulted by key players in nuclear medicine across Western Europe.
Whether you want to raise awareness of a radioligand, recruit for a clinical trial, or showcase a new theranostics solution: we will build with you a tailored offer matching your objectives and budget.
✉ Contact us for a tailored offer